PD-L1 anticorps (AA 18-227)

N° du produit ABIN5027432

Cet anticorps anti-PD-L1 est un anticorps Lapin Polyclonal détectant PD-L1 dans WB. Adapté pour Humain.

Aperçu rapide pour PD-L1 anticorps (AA 18-227) (ABIN5027432)

Antigène: PD-L1 (CD274 (PD-L1))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PD-L1 est non-conjugé

Application: Western Blotting (WB)

Détail du produit anti-PD-L1 anticorps

Épitope: AA 18-227

Purification: Protein A Chromatography

Immunogène: A partial length recombinant PDL1 protein (amino acids 18-227) was used as the immunogen for this antibody.

Isotype: IgG

Information d'application

Indications d'application: WB: 2-4 μg/mL

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: PBS containing 0.05 % BSA, PH 7.4

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody at 4°C, stable for 6 months. For long-term storage, store at -20°C. Avoid repeated freeze and thaw cycles.

Détails sur PD-L1

Antigène: PD-L1 (CD274 (PD-L1))

Autre désignation: PD-L1 / CD274

Sujet: Programmed death ligand 1/PD-L1 (also called B7-H1 and CD274) is a T cell inhibitory molecule that is expressed on antigen presenting cells (APC) leading to T cell anergy and/or apoptosis upon ligation to its receptor Programmed death-1 (PD-1, CD279) on T cells. PD-L1 is expressed on tumor cells of a subset of breast cancer patients. It could also induce EMT and enhance RCC cell cancer stemness through up-regulation of SREBP-1c. Blocking the immunosuppressive PD-1/PD-L1 pathway has antitumor activity in multiple cancer types, and PD-L1 expression on tumor cells and infiltrating myeloid cells correlates with the likelihood of response.

Poids moléculaire: 33 kDa

ID gène: 29126

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints